Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* An Institutional Review Board/Independent Ethics Committee (IRB/IEC) approved written Informed Consent form signed and dated by the subject or by parent(s) or legal representative~* Subjects from 16 to 70 years~* Subjects with a body weight of \>/= 40 kg~* Female subjects without childbearing potential or female subjects with childbearing potential if they use a medically accepted contraceptive method~* Subject/legal representative considered as reliable and capable of adhering to the protocol~* Subjects with well-characterized focal or generalized epilepsy or epileptic syndrome~* Subjects with a history of partial-onset seizures whether or not secondarily generalized or primary generalized seizures~* Subjects being uncontrolled while treated with 1 to 2 permitted concomitant antiepileptic drugs (AEDs)~* Permitted concomitant antiepileptic drugs (AEDs) and vagus nerve stimulation (VNS) being stable and at optimal dosage for the subject from at least 1 month before Visit 1 and expected to be kept stable during the Run-In and Evaluation Periods~Exclusion Criteria:~* Mentally impaired subjects unable to understand the study purpose~* History or presence of status epilepticus during 1 year preceding Visit 1 or Baseline~* Subjects on felbamate with less than 18 months continuous exposure before Visit 1~* Subjects currently on vigabatrin~* Subject taking any drug with possible relevant central nervous system effects except is stable from at least 1 month before Visit 1 and expected to be kept stable during the trial~* Subjects taking any drug that may significantly influence the metabolism of Brivaracetam (BRV) except if the dose has been kept stable at least 1 month before Visit 1, and is expected to be kept stable during the trial~* History of cerebrovascular accident in the last 6 months~* Subjects suffering from severe cardiovascular disease or peripheral vascular disease~* Presence of any sign suggesting rapidly progressing brain disorder or brain tumor~* Any clinical conditions which impair reliable participation in the study or necessitate the use of medication not allowed by protocol~* Presence of a terminal illness~* Presence of a serious infection~* Subjects with a history of sever adverse hematologic reaction to any drug~* Subjects suffering from severe disturbance of hemostasis~* Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) values of more than 3 times the upper limit of the reference range~* Subjects having clinically significant deviations from reference range values for laboratory parameters: creatinine clearance calculated \< 50 ml / min, platelets \< 100,000 / µL, or neutrophil cells \< 1,800 / µL~* Clinically significant electrocardiogram (ECG) abnormalities according to the Investigator~* History of suicide attempt~* In the Investigator's medical judgment, any current suicidal ideation or other serious psychiatric disorders requiring of having required hospitalization or medication~* Known allergic reaction or intolerance to pyrrolidone derivatives and / or investigational product excipients~* Known multiple drug allergies or severe drug allergy~* Pregnant or lactating women~* Known alcohol or drug addiction or abuse within the last 2 years~* Subject institutionalized under judicial decision~* Problems of venous accessibility~* Subject taking part in another clinical / pharmacological study in the month preceding enrollment (Visit 1)~* Investigators, coinvestigators, their spouses or children, or any study collaborators~* Subjects previously treated with Brivaracetam (BRV)~* Subject previously screened within this study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo tablets / Brivaracetam bolus (Type: EXPERIMENTAL): Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week
- Brivaracetam (BRV) tablets / BRV bolus (Type: EXPERIMENTAL): Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week
- Placebo tablets / Brivaracetam infusion (Type: EXPERIMENTAL): Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week
- Brivaracetam (BRV) tablets / BRV infusion (Type: EXPERIMENTAL): Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.~Down-Titration:~* If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~* If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete